Medicamen Biotech Ltd Share Price
(MEDICAMEQ)
₹430
as on 11:33AM, 30 Apr 2025
Medicamen Biotech Performance
Day's Low
Day's High
₹428Day's Price Range₹440.852 Week's Low
52 Week's High
₹375.0552-Week Price Range₹630
| Returns % | |
| 1 Month Return | -11.08 % |
| 3 Month Return | -4.83 % |
| 1 Year Return | -24.28 % |
| Market Stats | |
| Previous Close | ₹438.85 |
| Open | ₹439.65 |
| Volume | 14.88K |
| Upper Circuit | ₹526.60 |
| Lower Circuit | ₹351.10 |
| Market Cap | ₹557.98Cr |
Medicamen Biotech Fundamentals
P/E Ratio
83.59
PEG Ratio
-22.78
Market Cap
₹557.98 Cr
P/B Ratio
2.33
EPS
7.47
Dividend Yield
0.26
Sector
Pharmaceuticals
ROE
6.6
Key events for Medicamen Biotech Ltd
Medicamen Biotech Gains on European Distribution Deal - 08 Apr, 2025
Medicamen Biotech's stock surged by 11.5% following a distribution agreement with Denmark's XGX Pharma for three products in Europe. This rebound comes after a previous decline, helping to reduce year-to-date losses.Medicamen Biotech Secures CDMO Contract, Stock Soars - 03 Apr, 2025
Medicamen Biotech Ltd's stock jumped 12% after announcing a CDMO contract with XGX Pharma to develop and manufacture six products, enhancing its market position.Medicamen Biotech Gains After EU and USFDA Approvals - 28 Mar, 2025
Medicamen Biotech Ltd shares surged 8% following EU and USFDA approvals for its manufacturing plants. The company plans to expand into Canada and Australia while focusing on high-growth therapies like Oncology and Diabetes.Medicamen Biotech Expands in South Africa Market - 10 Mar, 2025
Medicamen Biotech Limited has entered an agreement with a South African conglomerate for product registration and marketing, boosting its stock by over 4%. Despite a slight revenue decline, net profit increased by 44% YoY.
Insights on Medicamen Biotech Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 3 quarters, 43.63 Cr → 45.28 Cr (in ₹), with an average increase of 1.8% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 0.05% to 0.12% in Mar 2025 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 1.35 Cr → 3.47 Cr (in ₹), with an average increase of 32.7% per quarter
- POSITIVE IMPACT
Promoter Holding Up
Promoters have increased holdings from 42.99% to 43.16% in Mar 2025 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 52.6% return, outperforming this stock by 76.9%
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 138.0% return, outperforming this stock by 176.4%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 56.04% to 55.98% in Mar 2025 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, MEDICAMEQ stock has moved down by -11.1%
Medicamen Biotech Financials
Medicamen Biotech Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 43.16% | 0.00 | |
| Foreign Institutions | 0.12% | 0.00 | |
| Mutual Funds | 0% | 0.00 | |
| Retail Investors | 55.98% | 0.00 | |
| Others | 0.75% | 0.00 |
Medicamen Biotech Key Indicators
Medicamen Biotech Valuation
Medicamen Biotech in the last 5 years
Lowest (41.41x)
March 13, 2024
Industry (54.77x)
April 29, 2025
Today (83.59x)
April 29, 2025
Highest (132.87x)
December 6, 2024
Medicamen Biotech Earnings and Dividends
Medicamen Biotech Ltd Earnings Results
Medicamen Biotech Ltd’s net profit jumped 44.58% since last year same period to ₹3.47Cr in the Q3 2024-2025. On a quarterly growth basis, Medicamen Biotech Ltd has generated 137.67% jump in its net profits since last 3-months.
Read More about Earnings ResultsMedicamen Biotech Ltd Dividends May,2024
In the quarter ending March 2024, Medicamen Biotech Ltd has declared dividend of ₹1 - translating a dividend yield of 0.46%.
Read More about Dividends
Medicamen Biotech Technicals Summary
Bearish
Neutral
Bullish
Medicamen Biotech Ltd is currently in a Bearish trading position according to technical analysis indicators.
Medicamen Biotech Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| NA | ₹557.98 Cr | -4.1% | 0.57 | ₹9 Cr | ₹179 Cr | |
| NA | ₹147.07 Cr | 35.43% | 0.62 | NA | NA | |
| NA | ₹5,411.31 Cr | 432.02% | 0.50 | ₹33 Cr | ₹204 Cr | |
| NA | ₹1,510.04 Cr | 381.87% | 0.52 | NA | NA | |
| NA | ₹3,596.41 Cr | 157.18% | 0.51 | NA | NA |
About Medicamen Biotech
Revenue: ₹45.14Cr as on December 2024 (Q4 24)
Net Profit: ₹2.92Cr as on December 2024 (Q4 24)
Listing date: 27 Oct, 2021
Chairperson Name: Rahul Bishnoi
| Organisation | Medicamen Biotech |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Medicamen Biotech Ltd
What is Medicamen Biotech Ltd price today?
Medicamen Biotech Ltd share price today stands at ₹430, Open: ₹439.65, Previous Close: ₹438.85, High: ₹440.8, Low: ₹428, 52 Week High: ₹630, 52 Week Low: ₹375.05.
How to Buy Medicamen Biotech Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Medicamen Biotech Ltd shares
What are today's traded volumes of Medicamen Biotech Ltd?
Today's traded volume of Medicamen Biotech Ltd(MEDICAMEQ) is 14.88K.
What is today's market capitalisation of Medicamen Biotech Ltd?
Today's market capitalisation of Medicamen Biotech Ltd(MEDICAMEQ) is ₹557.98Cr.
What is the 52 Week High and Low Range of Medicamen Biotech Ltd?
How much percentage Medicamen Biotech Ltd is down from its 52 Week High?
Medicamen Biotech Ltd (MEDICAMEQ) share price is ₹430. It is down -31.75% from its 52 Week High price of ₹630
How much percentage Medicamen Biotech Ltd is up from its 52 Week low?
Medicamen Biotech Ltd (MEDICAMEQ) share price is ₹430. It is up 14.65% from its 52 Week Low price of ₹375.05